Vipin Garg, MD
Pulmonary Disease · Staten Island, NYNPI 1881662062
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 329 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,435, 2.2 times the $654 reported in 2019.
Across 329 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Boehringer Ingelheim$736
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$690
- AstraZeneca$582
- Sanofi$307
- Insmed, Inc.$237
- plus $2K from 33 others
What the payments were for
- Food & beverage$6,04498%
- Education$1012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 98 | $1,429 |
| Boehringer Ingelheim | 42 | $736 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $690 |
| AstraZeneca | 33 | $582 |
| Sanofi | 20 | $307 |
| Insmed, Inc. | 22 | $237 |
| Abbott | 2 | $223 |
| Harmony Biosciences LLC | 8 | $209 |
| Philips North America LLC | 12 | $186 |
| Medtronic | 1 | $152 |
| Itamar Medical Inc | 1 | $114 |
| ANI Pharmaceuticals, Inc. | 7 | $113 |
| United Therapeutics Corporation | 7 | $109 |
| Sunovion Pharmaceuticals Inc. | 6 | $108 |
| Merck | 7 | $99 |
| Avadel CNS Pharmaceuticals, LLC | 6 | $96 |
| Pfizer | 4 | $74 |
| Eisai Inc. | 4 | $58 |
| Mallinckrodt Hospital Products Inc. | 4 | $57 |
| Amgen | 4 | $55 |
| Genentech USA, Inc. | 4 | $52 |
| Jazz Pharmaceuticals Inc. | 3 | $43 |
| Exact Sciences | 2 | $43 |
| Gilead | 3 | $39 |
| Mylan Specialty L.p. | 2 | $38 |
| Axsome Therapeutics, Inc. | 2 | $35 |
| Electromed, Inc. | 2 | $32 |
| Strongbridge US Inc. | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $25 |
| Bayer | 2 | $25 |
| Regeneron Healthcare Solutions, Inc. | 2 | $25 |
| Inogen, Inc. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$447
- AMPLATZER AMULET$198
- AURORA EV-ICD MRI SURESCAN$152
- OFEV$125
- AREXVY$125
- WatchPATONE$114
How this compares
$6,144 in reported general payments places this provider in the 75th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 13 | $628,034 |
| AdempasRiociguat | 13 | $150,743 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 176 | $130,487 |
| EliquisApixaban | 219 | $75,020 |
| Dupixent PenDupilumab | 12 | $53,039 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 62 | $45,238 |
| Incruse ElliptaUmeclidinium Bromide | 100 | $37,646 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $27,513 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $23,327 |
| Spiriva RespimatTiotropium Bromide | 38 | $22,250 |
| SantylCollagenase Clostridium Hist. | 16 | $20,380 |
| TivicayDolutegravir Sodium | 14 | $19,940 |
| SymbicortBudesonide/Formoterol Fumarate | 79 | $19,402 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 35 | $16,689 |
| EntrestoSacubitril/Valsartan | 21 | $13,573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $57 | $628,03413 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $1,429 | $227,214425 claims |
| BayerAdempas | $25 | $150,74313 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Farxiga, Brilinta | $582 | $78,251179 claims |
| PfizerEliquis | $74 | $75,020219 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat, Stiolto Respimat | $736 | $51,36097 claims |
| MerckDulera, Januvia | $99 | $20,63445 claims |
| NovartisEntresto | $15 | $13,57321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Staten Island
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
- Ali El AtatBrooklyn$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.